Abstract
We report the case of a boy with juvenile chronic myeloid leukemia (jCML), who after initial treatment with interferon alpha-2 (IFN) and hydroxyurea underwent bone marrow transplantation (BMT) from a matched unrelated donor complicated by graft failure. Subsequent stimulation of hematopoiesis by GM-CSF and IL-3 promoted autologous recovery. In contrast to the course of disease pre-BMT, the boy is now off any therapy remaining in complete remission more than 500 days after BMT.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bone Marrow / drug effects
-
Bone Marrow / pathology
-
Bone Marrow Transplantation*
-
Cell Survival
-
Combined Modality Therapy
-
Drug Synergism
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Hematopoiesis / drug effects*
-
Humans
-
Hydroxyurea / therapeutic use
-
Immunologic Factors / pharmacology
-
Immunologic Factors / therapeutic use*
-
Infant
-
Interferon Type I / therapeutic use
-
Interleukin-3 / administration & dosage
-
Interleukin-3 / pharmacology
-
Interleukin-3 / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Male
-
Remission Induction
Substances
-
Immunologic Factors
-
Interferon Type I
-
Interleukin-3
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Hydroxyurea